Pyrimidine Piperidine Compound for Glucose Metabolism Modulation

The patent applies parameter changes by developing a novel chemical compound with a specific molecular structure (Formula I) that modifies the pharmacological parameters of glucose metabolism. The compound achieves better blood glucose control by altering the interaction between insulin and cellular receptors, thereby improving normalization accuracy while reducing hypoglycemia risk through optimized molecular properties.

The invention employs a composite molecular structure combining multiple functional groups (aromatic rings, heterocyclic moieties, and substituent patterns) that work synergistically. This composite structure enables the compound to simultaneously address multiple pathological mechanisms including insulin resistance and glucose homeostasis, while maintaining a safer therapeutic profile with reduced hypoglycemia risk.

The patent implements universality by designing a multi-functional compound that simultaneously addresses insulin resistance, enhances β-cell function, and improves glucose metabolism. The molecular structure of Formula I is engineered to interact with multiple targets in the insulin signaling pathway, providing comprehensive treatment for diabetic pathophysiology rather than addressing single mechanisms.

The compound structure is segmented into distinct functional regions including aromatic rings, heterocyclic cores, and variable substituent groups (R1-R6). These segments can be independently optimized to target different aspects of insulin resistance and β-cell dysfunction, allowing the molecule to perform multiple therapeutic functions simultaneously with high reliability.